Angiography Versus Intravascular Ultrasound-Directed Stent Placement (AVID)

Dharam J. Kumbhani, M.D., S.M.; Deepak L. Bhatt, M.D., F.A.C.C.

Disclosures

Cardiosource 

Description

Given conflicting data regarding the benefit of the routine use of intravascular ultrasound (IVUS) to guide stent implantation, the AVID trial tested the hypothesis that IVUS-guided bare-metal stent placement would be superior to stent placement guided by angiography alone.

Hypothesis

IVUS-guided bare-metal stent placement would be superior to stent placement guided by angiography alone.

Drugs/Procedures Used

No IVUS was performed before stent placement in either group. In the angiography-directed (AG) arm, procedural success was defined as <10% stent diameter stenosis compared with the distal reference vessel, by visual estimation. IVUS was performed after this in a blinded fashion. In the IVUS-directed (ID) arm, identical criteria as above were applied for angiographic success. IVUS was then performed in an unblinded fashion, and assessed for optimal stent placement, based on IVUS criteria, such as full apposition, smallest cross-sectional area (CSA) ≥90% of the distal reference vessel CSA, and absence of noncovered dissections.

Concomitant Medications

Ticlopidine 250 mg was administered twice a day for 2-4 weeks, which could be replaced by clopidogrel 75 mg daily for 2 weeks after August 1998. Aspirin 325 mg/day was administered for an indefinite period. No patients received glycoprotein IIb/IIIa inhibitors.

Principal Findings

A total of 800 patients were randomized, 406 to the AG arm, and 394 to the ID arm. Baseline characteristics were fairly similar between the two arms. About 19% had prior coronary artery bypass grafting (CABG) and 25% had prior percutaneous coronary intervention (PCI). The vessel treated was the left anterior descending in 39%, and right coronary artery in 34%. More than one vessel was stented in 8% of the patients. The mean lesion length was 13.0 mm, with an distal reference vessel diameter (RVD) of 2.81 mm, although about 31% of the vessels had a RVD of <2.5 mm by angiographic core laboratory analysis. In the ID arm, of those who did not meet IVUS criteria for optimal stent placement, only 37% of patients received further therapy for an underexpanded stent. Additional therapy in the ID arm was mainly necessary for residual stenosis >10% (29.2%) and nonapposition (10.7%). The ID arm had a higher stent usage (1.53 vs. 1.38, p = 0.01), as well as a larger maximal balloon size (3.71 vs. 3.53, p < 0.001). Final stent area expansion compared with the CSA of the distal reference vessel lumen was significantly better in the ID arm (90.4% vs. 84.6%, p < 0.001). At 12 months, there was no difference in the incidence of target lesion revascularization (TLR) between the AD and ID arms (12.0% vs. 8.1%, p = 0.08), although a difference was noted in patients with a prestent RVD ≥2.5 mm (10.1% vs. 4.3%, p = 0.01), and prestent % stenosis >70% (14.2% vs. 3.1%, p = 0.002). There was similarly no difference in the incidence of death (1.9% vs. 3.3%, p = 0.39), myocardial infarction (MI) (5.1% vs. 6.8%, p = 0.32), or stent thrombosis (1.1% vs. 1.4%, p = 0.75).

Interpretation

The results of the AVID trial indicate that IVUS-directed bare-metal stenting is not associated with improved clinical outcomes in patients undergoing elective PCI, although certain patients such as those with an RVD of >2.5 mm, and present stenosis of >70% may benefit. Interestingly, although mandated in the protocol of this trial, only 37% of underexpanded stents received additional therapy in the IVUS-directed arm. This may have biased the results of the primary endpoint toward the null. Earlier IVUS trials had failed to show a definite benefit with the use of IVUS for routine PCI. This trial seems to suggest that certain patients may derive benefit by reduction in TLR with IVUS guidance. However, this trial was conducted more than 10 years ago, and there have been several procedural and technological advances in PCI since then, including in the use of periprocedural therapy. It is thus unknown if these results are valid in a contemporary population. Moreover, it is unclear if a similar benefit would be noted with drug-eluting stents, which have a significantly lower incidence of TLR to begin with.

Conditions

  • Coronary heart disease / Angina pectoris / Stable

Therapies

  • Stent

  • Intravascular Ultrasound (IVUS)

Study Design

Randomized. Parallel.
Patients Enrolled: 800
Mean Follow-Up: 12 months
Mean Patient Age: 62.5 years
% Female: 30
Mean Ejection Fraction: 54%

Primary Endpoints

  • TLR at 12 months

Secondary Endpoints

  • All-cause mortality at 12 months

  • MI at 12 months

  • Stent thrombosis at 12 months

  • CABG at 12 months

  • Major adverse cardiac events at 12 months

  • All the above endpoints, including the primary endpoint at 30 days and 6 months

Patient Population

  • Age >18 years

  • Elective PCI

  • RVD ≥2.5 mm by visual estimation

Exclusions:

  • Coronary dissection not covered by a stent

  • TIMI flow grade <3 post-stent placement

  • Chronic total occlusion

  • Stent placement in sole remaining circulation or left main equivalent

  • Stent placement within an aneurysmal portion of a vessel such that complete stent-vessel wall contact could not be achieved

  • A bypass graft supplying a native vessel <2.0 mm by visual estimate

  • Cardiac transplantation

  • Performance of IVUS during the index procedure before stent placement

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....